Drugs that contain Aztreonam
1. Cayston patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399496 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7208141 | GILEAD | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7214364 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7427633 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 22, 2017 |
Market Authorisation Date: 22 February, 2010
Treatment: Improve respiratory symptoms in cystic fibrosis in patients with pseudomonas aeruginosa
Dosage: FOR SOLUTION;INHALATION
More Information on Dosage
CAYSTON family patents
